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Abstract. Antibodies to CD44 have been used to in- 
hibit a variety of processes which include lymphohe- 
mopoiesis, lymphocyte migration, and tumor metasta- 
sis. Some, but not all, CD44-mediated functions derive 
from its ability to serve as a receptor for hyaluronan 
(HA). However, sites on CD44 that interact with either 
ligands or antibodies are poorly understood. Interspe- 
cies rat/mouse CD44 chimeras were used to analyze the 
specificity of 25 mAbs and to determine that they rec- 
ognize at least seven epitopes. Amino acid substitutions 
that resulted in loss of antibody recognition were all lo- 
cated in the region of homology to other cartilage link 
family proteins. While at least five epitopes were elimi- 
nated by single amino acid replacements, multiple resi- 
dues had to be changed to destroy binding by other an- 
tibodies. One antibody was sensitive to changes in any 
of three separate parts of the molecule and some anti- 
bodies to distinct epitopes cross-blocked each other. 
Certain antibodies had the ability to increase HA bind- 
ing by lymphocytes but this did not correlate absolutely 
with antibody specificity and was only partially attribut- 
able to CD44 cross-linking. Antibodies that consis- 
tently blocked HA recognition were all sensitive to 
amino acid changes within a short stretch of CD44. 
Such blocking antibodies interacted with CD44 more 
strongly than ligand in competition experiments. One 
large group of antibodies blocked ligand binding, but 
only with a particular cell line. This detailed analysis 
adds to our understanding of functional domains within 
CD44 and requirements for antibodies to influence rec- 
ognition of one ligand. 
M  ONOCLONAL antibodies have provided powerful 
tools  for  identifying  and  characterizing  cell- 
adhesion molecules. They usually reflect species 
differences in amino acid sequences between the source of 
the immunogen and the animal being immunized. Certain 
antibodies influence adhesive functions and others are in- 
formative  about  ligand-binding  states.  Particularly  well 
studied in this regard are antibodies to integrins,  which ap- 
pear to undergo conformational changes in response to in- 
tracellular or extracellular signals (2, 38, 48). One antibody 
that binds only to an  "activated" integrin  may do so by 
mimicking the natural ligand (1). Some antibodies dramat- 
ically increase the affinity of integrins for ligand,  perhaps 
by stabilizing  a particular active conformation (9, 38). Still 
other reagents block or change the specificity for ligands 
and there are antibodies which recognize binding site oc- 
cupancy (10, 36). Finally,  antibodies have been described 
that recognize combinations of particular et and 13 integrin 
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chains (3, 5). Interspecies chimeras have been successfully 
used to "map" the recognition specificity of antibodies to 
particular regions of integrins (6, 47, 52). 
CD44 has attracted considerable interest because of its 
possible  importance  in  lymphohemopoiesis,  tumor  me- 
tastasis,  lymphocyte activation, and leukocyte extravasa- 
tion.  These functions may in part relate to the ability of 
CD44 to act as a receptor for soluble or cell-bound hyal- 
uronan (HA)  1 (4, 25, 27, 32). Cells bearing CD44 can have 
different functional "states" with respect to ability to rec- 
ognize this ligand (reviewed in 25). For example, resting B 
lymphocytes do not bind HA, and become able to do so 
only after  prolonged  incubation  with  activation  stimuli 
such  as  IL-5.  T  lymphocytes represent  a  second  state, 
where ligand binding is markedly up-regulated by a partic- 
ular mAb, IRAWB14. Fully activated normal lymphocytes 
and comparable cell lines typify a third state, as they con- 
stitutively recognize HA with apparent high affinity. 
Many antibodies have been prepared  to multiple  epi- 
topes on CD44 of various species.  However, with the ex- 
1. Abbreviations used in this paper.  HA, hyaluronan; FL-HA, fluorescein 
labeled HA; MFI, median fluorescence intensity. 
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used by lymphocytes, most have not been well character- 
ized with respect to specificity. The actual binding site for 
HA has not yet been identified and essentially nothing is 
known about how antibodies can influence HA recogni- 
tion.  We  now  characterize antibodies  that  recognize at 
least  seven epitopes  on  CD44. All  antibodies  that  uni- 
formly blocked ligand recognition were dependent on resi- 
dues in a single CD44 loop. Antibodies that were similarly 
sensitive to substitutions in another part of the molecule 
differed in their ability to enhance ligand binding. Still an- 
other portion of CD44 contained a single residue polymor- 
phism which accounts for the specificity of antibodies that 
only block HA recognition by one cell type. 
Materials and Methods 
Cell Lines 
The CD44-negative murine lymphoma AKR1 (15) was used to prepare 
stable  transfeetants  with  chimeric  cDNAs.  The  AKR1.CD44WT  and 
AKR1.CD44ANC clones are  stable transfectants which have been de- 
scribed previously (13, 24). The human 293T renal cell carcinoma line (33) 
expresses extremely low levels of human CD44 and was used for transient 
transfection experiments. Other cell lines including BW5147 (a T  lym- 
phoma), WB (a derivative of SAKRTLS12.1, described in 16), and W279 
(a B  lymphoma) were maintained in Dulbecco's minimal essential me- 
dium with 10% FCS. The BM2 B cell hybridoma was grown in RPM11640 
with 10% FCS. All cell lines have been used in our previous studies of 
CD44 function (16, 23, 24, 32). 
Chimeric Plasmid Construction 
Our previous constructs of the hemopoietie form of murine CD44.1 were 
prepared from eDNA generously donated by Dr. E. Butcher and have 
been described (13, 24). Nucleotide and amino acid numbering are as in 
those publications. Murine CD44.1 was cloned into the pBS+/-  vector 
(Stratagene Inc., La Jolla, CA) to yield a plasmid designated mWTpBS. A 
1.0-kb rat CD44 full-length eDNA in the EcoRI site of vector pTTT3-S was 
provided by Dr. U. Gunthert of the Basel Institute for Immunology (12). 
We designated it rWTpT7T3S. 
Megaprimer PCR-directed mutagenesis  was used to generate three rat/ 
mouse CD44 chimeric expression plasmids which contain large segments 
(63, 85, and 107 residues) of rat CD44 at the 5' end instead of murine se- 
quence. These were designated R/MI, R/MI+II, R/MI+II+III,  and are 
indicated in Fig. 1, which shows part of the extracellular domain of routine 
and  rat  CD44.  Two  previously  described  oligonueleotides  were  used 
throughout this study for PCR priming (13). The 29-bp upstream primer 
OM-6AR,  corresponds  to  a  21-bp  stretch  overlapping  the  initiation 
eodon ATG in the murine and rat CD44 eDNA clones mWTpBS and 
rWTpTTT3S, whereas the downstream primer OM-2AR is complementary 
to a 19-bp fragment around the stop codon TAG in the mWTpBS clone. 
Both oligonucleotides had an EeoRI site added to the 5' end for use in 
cloning. Antisense primers of R/MI, RfMI+ II, and R/MI+II+III were de- 
signed to amplify the three large fragments of rat eDNA. PCR reactions 
were cycled 25 times at 94°C for 1 min, 50°C for 2 min, and 72°C for 3 rain. 
First-round PCR was primed by OM-6AR and the antisense primer of 
each chimera using the rat eDNA as template. The amplified 5' end frag- 
ments of rat sequence were purified from agarose gels. We used mouse 
eDNA as template for second-round PCR, amplified rat 5' end fragments, 
and OM-2AR as primers to obtain rat/mouse chimeric eDNA. This was 
then subcloned into an EcoRI site of the pBS+/- plasmid. 
Construction of Chimeras Using 
Site-directed Mutagenesis 
PCR-introduced site-directed mutagenesis was used to change single or a 
cluster of residues of the mouse CD44 sequence to rat. Sites that differed 
between mice and rats that were substituted are boxed and indicated by 
small letters in Fig. 1. For the first round of PCR, mWTpBS was used as 
template. OM-6AR and an antisense primer for each chimera were used 
as a set to amplify the 5' end fragment of the mouse eDNA. In each case, 
the  antisense primer  contained  the  introduced  rat  sequence. A  sense 
primer for each chimera containing the introduced rat sequence and com- 
plementary to the above antisense primer, was then used with OM-2AR 
to amplify the 3' end fragment of the mouse eDNA. PCR conditions were 
as described above and products from both PCR reactions were then puri- 
fied from agarose gels. For the second round PCR, we used the two puri- 
fied PCR fragments as template, with OM-6AR and OM-2AR as primers 
to amplify the complete rat/mouse chimeric eDNA. The amplified prod- 
ucts were then run on agarose gels, and 1.1-kb bands were purified using 
Geneclean (BIO  101,  Inc., Vista, CA),  digested with EcoRI,  and sub- 
cloned into pBS+/-. 
All of the chimeric clones contained full-length mouse CD44 eDNA. 
R/Ma contains a single Ile of rat sequence instead of Val-8. R/Mb contains 
a single residue change from Gln-36 to Glu. R/Me contains a single resi- 
due change from Ser-40 to Thr. R/Md contains three residues changed 
(Asp-46 to Ala, Lys-49 to Glu, Ser-53 to Arg). R/Me contains a single res- 
idue changed from Asn-67 to His. R/Mf has a single residue changed from 
His-83 to Asn. RMg contains two residues changed (Val-90 to Leu, Thr-91 
to Ala). R/Mh contains a single residue changed (Pro-108 to Leu). 
Sequencing and Construction of  Expression Plasmids 
Chimeric cDNAs were cloned into pBS+/- vector and sequences deter- 
mined  using  the  dideoxy  chain  termination  method  with  Sequenase 
(United States Biochemical Corp., Cleveland, OH) from double-stranded 
templates. The chimeric eDNA inserts of R/Md, R/Mg, and R/Mh were 
subcloned via blunt-end ligation into a HindIII site of the expression vec- 
tor pRc/RSV (Invitrogen, San Diego, CA) which has an LTR promoter 
from  Rous  sarcoma  virus,  a  polyadenylation  signal  from  the  bovine 
growth hormone and a neo r gene for selection in G418 supplemented me- 
dia. A  BstXI/EcoRI adaptor  (Stratagene Inc.) was added to other chi- 
meric eDNA inserts before cloning into the BstXI site of the expression 
vector pEF-BOS (33). This vector has a human EF-1 promotor, the stuffer 
fragment from CDM8 vector, and a polyadenylation signal from human 
G/M-CSF eDNA. 
Transfection of Cells 
Mouse wild-type CD44 and the chimeric structures RAid, RMg, RMh in 
the pRc/RSV vector were transfected into AKRI cells by electroporation 
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Figure  1.  Comparison  of  amino  acid  sequences  for 
part  of the  extracellular  regions  of murine  and  rat 
CD44. Numbering of residues starts at the beginning 
of the  mature  protein.  Regions  exchanged  in  large 
segment chimeras are indicated by roman numerals. 
Single  or  clustered  residue  substitutions  are  boxed 
and indicated by small letters. 
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25 IxF of capacitance as described previously (13).  G418 was added at 1 
mg/ml after 48 h of growth and drug-resistant colonies appeared within 2 
wk. Mouse wild-type CD44 and all other chimeric CD44s in the pEF-BOS 
vector were transfected into 293 T cells with a standard calcium phosphate 
method. The transfectants were stained with CD44 mAbs and analyzed by 
flow cytometry with a FACScan  ® (Becton Dickinson Immunocytometry 
Systems, Mountain View, CA). 
Antibodies and Flow Cytometry 
Many of the rat anti-mouse CD44 mAbs have been previously described 
and include IM7.8.1  (IgG2b) (55); I42/5 (IgG2a) (55); RAMBM55.5 (IgM), 
RAMBM5.5.8 (IgM), RAGN185.6 (IgM), RAMBM17.4.3 (IgM), R7166.7 
(IgM),  REL72.1  (IgG2a)  (23);  RAMBM44.5.2  (IgM)  (21);  IRAWB14.4 
(IgGEa) (24); IRAWB26.6 (IgG2a) (26); RAW45.106.2 (IgM), IRAWB27.3 
(IgG])  (Lesley, J.,  R.  Schulte, and R. Hyman, unpublished data);  and 
KM201 (IgG1),  KM81 (IgGEb), KMl14 (IgG1) (31).  One group of previ- 
ously unpublished antibodies, KM703 (IgG2a) and KM03, arose from the 
same series (31).  C71/26.4  (IgM) recognizes a polymorphism (CD44.2), 
and RAMBM44.5.2 (IgM) is specific for the CD44.1  allele (21).  The rat 
D12  (IgG2b)  and the hamster anti-mouse 1.5.1 (IgG)  CD44  antibodies 
were prepared by immunization of Sprague Dawiey rats and Syrian ham- 
sters, respectively (Fan', A., unpublished data). 1B6 is a recently prepared 
antibody which induces spreading of activated B  lymphocytes (Santos- 
Argumedo, R. W. Kincade, and R, M. E. Parkhouse, manuscript submit- 
ted for publication) and methods used for its preparation have been de- 
scribed elsewhere (46).  The previously unreported SK45.9  (IgM), SK47 
(IgG2a), and SK159 (IgG2a) antibodies were made by fusion of Sp2/0 with 
spleen cells from Fisher rats immunized with affinity-purified CD44 from 
KLN205 tumor cells. OX49 (IgG2a) and OX50 (IgG1)  are mouse anti-rat 
CD44 mAbs (39), and were generously donated by Dr. Nell Barclay (Uni- 
versity of Oxford, Oxford, UK). Most of the flow cytometry experiments 
were conducted with hybridoma culture supernatants, but antibodies were 
purified by protein G  chromatography (Pierce Chemical Co., Rockford, 
IL) and used in cross-blocking and other studies. The HPC4 antibody and 
its use with an epitope tag sequence have been described (43, 50). 
Fluorescein-conjugated HA (FL-HA) was prepared and used at a final 
concentration of 36  }xg/ml as described in our previous studies (13, 24). 
Transfected cells were first stained with ~1  p~g of each anti-CD44 anti- 
body, followed by FITC-labeled mouse anti-rat Ig in the case of rat anti- 
bodies, goat anti-mouse Ig for the two mouse anti-rat CD44 mAbs, or 
goat anti-hamster Ig for the 1.5.1 antibody. All the transfections and flow 
cytometry analyses were repeated at least three times. The 1.5.1 hamster 
mAbs efficiently recognized both rat and mouse CD44 and served as a 
standard for normalizing expression levels. The median fluorescence in- 
tensity of staining achieved with this antibody on wild-type murine CD44 
transfectants was assigned a value of 1.0. Each of the other transfectants 
prepared on the same day were analyzed in the same way and the level of 
expression normalized to the wild-type result. When staining of a chimera 
(median fluorescence intensity) was reduced more than fivefold relative 
to that of wild-type CD44, it was indicated by -  in Table I. All other re- 
sults were consistently within twofold of wild-type values. In Table II, an- 
tibodies which gave <20%, 20-40%, or >40% of wild-type staining with 
chimeric CD44 were designated -, +_, or +, respectively. 
Construction  of Epitope-tagged CD44 
The pEFBos expression vector was engineered to include the transmem- 
brane segment of tissue factor (44) and 14 amino acids recognized by the 
HPC4 mAb (43, 50). A  cDNA corresponding to the entire extracellular 
domain of the hemopoietic form of CD44 was then ligated into this vector. 
The  resulting construct was  then expressed in  AKR1  cells and  stable 
transfectants with high level expression were selected by cell sorting and 
cloning by limiting dilution. These cells were used to study the influence 
of antibody-mediated receptor oligomerization on HA binding and simi- 
lar results were obtained with six different clones. 
Results 
Reactivity of mAbs to Rat/Mouse CD44 Chimeras 
Preliminary experiments showed that none of 22 rat mAbs 
recognized rat CD44. However, all were positive on a pre- 
viously prepared transfectant designated AKR.CD44ANC 
(13). These cells express a truncated murine CD44 mole- 
cule which contains only the NH2-terminal 163 amino ac- 
ids of the protein. We then exploited the extensive conser- 
vation between murine and rat CD44 sequences to localize 
residues encoding epitopes recognized by these antibod- 
ies. A  hamster mAb (1.5.1) that recognized both rat and 
mouse CD44 served as a useful control for normalizing ex- 
pression levels (see Materials and Methods). 
Interspecies  chimeras  were  constructed  with  increas- 
ingly large segments of rat CD44 cDNA sequence intro- 
duced into an otherwise mouse CD44 (Fig. 1). The result- 
ing constructs were then used for transient transfection of 
human 293T cells, which constitutively express extremely 
low levels of CD44. Typical results from flow cytometry 
characterization are shown in Fig.  2  and the  results  are 
summarized  in  Table  1.  CD44  which  included  only the 
NH2-terminal 63 amino acids of rat sequence (segment I) 
was still recognized by the majority of antibodies. How- 
ever, residues  in  this  most NH2-terminal portion of the 
molecule were needed for recognition by a group of seven 
rat anti-mouse antibodies. Additionally, one mouse anti- 
rat CD44 antibody (OX50) was now positive. Introduction 
of a larger portion of rat CD44 sequence (segments I and 
II, the first 85 amino acids) resulted in loss of reactivity by 
an  additional  six  rat  anti-mouse  antibodies,  along with 
gain of reactivity by one mouse anti-rat CD44 antibody 
(OX49). Exactly the same pattern of reactivity was seen 
with transfectants prepared with  an even larger portion 
(107 residues) of rat CD44 sequence (included segments I, 
II, and III). Therefore, residues required for recognition of 
CD44 by the remaining group of ten rat anti-mouse anti- 
bodies were localized to a region between amino acids 108 
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Figure 2.  Example of epitope loss on chimeric CD44. These typi- 
cal flow cytometry results were obtained by staining 293T  cells 
transfected with CD44  cDNA. The IM78.1  antibody recognizes 
both wild-type and chimeric R/M I  CD44, while the latter is not 
stained by the IRAWB26 antibody. 
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Chimeras by Antibodies 
Transfectants  were prepared  and  analyzed  as  detailed  in  Materials  and  Methods. 
Staining of rat/mouse chimeras was designated as -  or +  when it was reduced more 
than fivefold, or less than twofold of that obtained with wild-type CD44.  R/M, rat/ 
mouse. 
and 163 (Table I). All of the constructs were found to con- 
fer hyaluronan-binding  ability on transfected cells  (data 
not  shown).  We  conclude from this,  and  the  reciprocal 
loss/gain of murine/rat epitopes, that the chimeric proteins 
retained structural integrity. 
More extensive characterization of the antibodies was 
then done with chimeric constructs which had single, clus- 
tered, or combinations of rat amino acids placed into the 
murine sequence (see Fig. 1, a-h). The first three substitu- 
tions (a-c) had no effect on the binding of any of the rat 
anti-mouse antibodies (Table II). Chimeric murine CD44 
which included three residues from the rat sequence (d) 
was no longer recognized by five of the antibodies. One of 
these (SK159) failed to recognize CD44 with substitution 
of just aspartic acid-46, while this had no effect on binding 
of IRAWB14  and  three  other antibodies  in  this  group. 
Also, a  large segment rat/mouse chimera which had  the 
murine residue (serine) at position 53 was not recognized 
by any of these four antibodies  (results not indicated in 
Table  II).  Thus,  the  rat/mouse  difference  at  lysine-49 
probably determines this antigen specificity. 
Analysis of chimeric CD44 revealed that one set of two 
antibodies (KMll4 and KM81) had indistinguishable speci- 
ficity (Table II).  Their reactivity was  completely depen- 
dent on histidine-83 (f). These antibodies efficiently recog- 
nize hamster cells (data not shown) which are identical to 
mice at this position (4). 
The specificity of a  set  of ten  reagents,  including  the 
IM7.8.1  mAb, was dependent totally on a  single proline- 
108 (h). Many of the antibodies in this group were previ- 
ously known  to  cross-react with  human  CD44  (17,  and 
Table II. Recognition of Single/Multiple Residue Rat~Mouse CD44 Chimeras by Antibodies 
Transfectants were prepared and analyzed as detailed in Materials and Methods (see also Fig. 1). The results are given as -,  -, or +  when staining of chimeras was <20, 20-40, 
or >40%, respectively of that seen with wild-type CD44. 
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CD44 share the same amino acid at this position. 
A  single residue (glutamine-36, b) determined the bind- 
ing of the OX50 mouse anti-rat CD44 antibody, and re- 
placing only asparagine-67 (e) with histidine allowed rec- 
ognition by the OX49 mouse anti-rat antibody (Table II). 
The SK159 antibody had unique and complex recogni- 
tion specificity. Binding of this interesting reagent was ab- 
rogated by changing residues in  any of three well-sepa- 
rated  areas  (d,  e,  and  g).  As  noted  above,  it  was  only 
necessary to change aspartic acid-46 in the "d" cluster of 
residues for loss of this epitope (results not indicated in 
Table II). 
Other antibodies were complex in a different way, and 
multiple,  noncontiguous  residues  had  to  be  changed  to 
lose reactivity. For example, while substitution of the as- 
paragine-67 (e) caused greatly reduced staining by the 1B6 
antibody, it was completely lost only when it was changed 
together with other residues (e+f+g). 
Staining of the "f" chimera (histidine-83 to asparagine) 
by the KM201 antibody was diminished ~70%. However, 
recognition was lost completely only when an additional 
two residues (valine-90 and threonine-91, g) were changed 
at the same time. While single changes at d  and e  alone 
had no effect, KM201 recognition was completely lost with 
the combination d,e,f. In another study, we found that tu- 
nicamycin treatment of murine lymphoma cells did not in- 
fluence staining with KM201, but the same treatment abol- 
ished recognition of CHO cells (18). This indicates that 
species cross-reactivity of this reagent may be dependent 
partially  on  carbohydrate.  Two  other  CD44  antibodies 
(KMll4 and KM81) also recognized hamster cells and the 
staining was diminished, but not lost, by tunicamycin treat- 
ment. 
The  RAMBM55.5  antibody  had  a  reactivity  pattern 
which was similar, but not identical to KM201. The D12 
antibody also had complex recognition specificity. While a 
single change at position 83 (f) greatly reduced recogni- 
tion, an additional change six residues away (g) was needed 
to completely abolish staining. 
The epitope(s) for two antibodies (RAMBM44.5.2 and 
KMO3)  was  not  lost  by any of the  single  or  clustered 
amino acid substitutions but our analysis revealed that res- 
idues within the first 63 amino acids (segment I) are criti- 
cal (see Table I). The first residue in the protein (histidine 
versus glutamine) represents the only difference between 
mice and rats in this region that we did not substitute and 
it presumably determines the RAMBM44.5.2 epitope. The 
same antibody is known to recognize a polymorphism of 
CD44 (CD44.1; BALB/c mice are positive, AKR mice are 
negative). The KMO3 antibody was indistinguishable from 
RAMBM44.5.2 in recognition of the chimeras, but was not 
investigated with respect to mouse strain polymorphism. 
BALB/c mice are known to differ from C3H mice at posi- 
tion 174 and to have two fewer amino acids at the signal 
peptide cleavage site (13, 37, 56, 59). Therefore, the pres- 
ence or absence of two amino acids (histidine and proline) 
at the amino terminus could account for the CD44.1 versus 
CD44.2 polymorphism. 
This analysis provided a detailed profile of differences 
between mouse and rat CD44 that are immunogenic, we 
then considered information about recognition specifici- 
ties of the various antibodies together with their influence 
on CD44 functions. 
Monoclonal Antibodies to Distinct CD44 Epitopes 
Cross-block Each Other 
All of the antibodies shown to be members of the same 
group (Table II), also cross-blocked each other (data not 
shown). However, it was surprising to find that some anti- 
bodies  from different  groups  cross-blocked, and  a  dra- 
matic example is shown in Fig. 3. This pair of reagents is 
particularly interesting because  IRAWB14  can  enhance 
ligand binding in some circumstances whereas KMl14 al- 
ways blocks (see below). Pretreatment of cells with excess 
unlabeled  IRAWB14  antibody  completely  prevented 
staining by FITC labeled KMll4 (Fig. 3, left panel). Fur- 
thermore, the  order of pretreatment with the  unlabeled 
forms of these antibodies determined whether or not cells 
recognized fluorescent HA (center and right panels). Cells 
which first received IRAWB14 recognized this ligand and 
a substantial level of staining was observed by flow cytom- 
etry. However, essentially no binding was seen when the 
blocking KMl14  antibody was  used as the  first step  re- 
agent. One can conclude that the epitopes recognized by 
these unrelated antibodies are in close proximity, or that 
binding of one reagent alters CD44 conformation so that 
the other epitope is lost. 
Antibody Specificity and Influence on Ligand Binding 
Most of the antibodies in this panel have been compared 
for their ability to block or enhance HA recognition by 
transfected AKR.CD44WT or similar cells, and a general 
summary is given in Table III. Two antibodies with similar 
specificity (KMll4 and KM81), and antibodies with par- 
tially related specificity (KM201, RAMBM55.5, and D12), 
blocked FL-hyaluronan binding by many cell lines (for an 
example, see Fig. 7 below). The ligand recognized by the 
SK159 antibody is unique and sensitive to changes in any 
of three locations on CD44  (Table II).  It also interfered 
with ligand binding by multiple cell types. A common fea- 
ture of these reagents is their dependence on histidine-83, 
UnsMIned 
Fluorescence Intenolty 
Figure 3.  Antibodies to distinct epitopes cross-block each other. 
The left panel shows immunofluorescence staining of AKR1.CD- 
44WT cells treated with FITC-labeled KM114 antibody alone, or 
after pretreatment with an excess of unlabeled  IRAWB14 anti- 
body. Similar results were obtained with other antibodies  from 
these two groups and when the antibodies were added in reverse 
sequence. The middle panel illustrates the inability of the same 
cells to bind flourescein-labeled hyaluronan (HA) after pretreat- 
ment with KM114, followed immediately by IRAWB14, followed 
by the labeled ligand. The right panel shows that fluorescent HA 
was  bound  if  the  order  of  pretreatment  was  reversed,  i.e., 
IRAWB 14, followed by KM114, 
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to Enhance Ligand Binding 
Effect on HA 
Epitope group  Antibody  Isotype  binding 
IRAWB26  IgG2a  1" 
d  IRAWB 14  IgG2a  ~'1" 
RAWB45  IgM  $ 
REL72  IgG2a  ,~ 
f  KM81  IgG2b  ~, 
f  KMll4  IgG~  $ 
f (complex)  KM201  IgGl  $ 
f (complex)  RAMBM55  IgM  $ 
f (complex)  D 12  IgG2b  ~, 
d,e,g  SKI59  IgGza  $ 
IN[7  IgGzb 
R7166.7  IgM  1" 
SK47  IgG2a 
RAMBM5.5  IgM 
h  RAGN 185.6  IgM  "~ 
142/5  IgG2a 
KM703  IgG2a  (~-) 
RAMBM17.4  IgM 
IRAWB27.3  IgGx 
SK45.9  IgM  ($) 
This represents a general summary of the influence of antibodies on HA recognition. 
See Figs. 4 and 7 for specific examples. 
or  the  nearby  valine-90/threonine-91  for  recognition  of 
CD44. 
Results obtained with a subclone of the WB lymphoma 
that does not constitutively bind HA are illustrated in Fig. 
4. Four antibodies that were indistinguishable by interspe- 
cies chimera analysis (epitope d) had dissimilar influence 
on  the  ability  of  cells  to  bind  HA.  For  example,  the 
IRAWB14 and REL72  antibodies are both of the IgG2a 
isotype, but only the former increased ligand binding.  In 
fact, REL72 actually blocked ligand binding by other cells 
which  constitutively had this  function  (not  shown).  Fur- 
thermore, one antibody in the h  epitope group, R7166.7 
(IgM), increased ligand binding ~10-fold. However, nine 
other  antibodies  in  this  category had  no  influence.  The 
ability of antibodies to increase ligand binding may not be 
solely determined by epitope specificity. 
Alone  I ~  I 
~=  IRAWB14  I  '  ~l  ;; ~! A 
|  -,.  ,. 
]  ii  It2  :i~'  I~  i"  "  "  t~  ....  ~q~  "  "-'/~  "  "" "iqP  .............  '  ..... 
Flumms~nce Intensity (RTC-HA) 
Figure 4.  Antibodies with indistinguishable  specificity differ in 
ability to enhance ligand binding. A non-HA-binding subclone of 
the WB lymphoma was first exposed to the indicated  antibodies 
before addition  of FL-HA. The extent of binding  was then as- 
sessed by flow cytometry. All of the antibodies  except R7166.7 
(group h) were in the d group (Table II). Nine other antibodies of 
the h epitope group were tested in the same assay and found to 
have no influence on ligand binding. 
Oligomerization of Cell Surface CD44 and its Influence 
on Ligand Binding 
Monomeric Fab fragments of the IRAWB14 and IRAWB26 
antibodies have reduced  affinity for CD44  and  only en- 
hanced hyaluronan recognition by lymphoma cells when 
used with a second antibody (26). This indicated that en- 
hancement might result in part from receptor cross-link- 
age. In agreement with that, dimerization of the receptor 
also lowered the threshold amount of CD44 required for 
detectable binding of HA (41).  Although  there  are IgM 
and IgG antibodies which seem to have no effect on ligand 
recognition, these might in part interfere with the binding 
site because they recognize epitopes within  the  first 163 
residues.  We wondered  if antibodies  directed  to  a  com- 
pletely different part of CD44 might influence HA bind- 
ing. A  small HPC4 sequence tag was inserted into CD44 
cDNA such that the epitope would be situated on the ex- 
pressed protein near the cell membrane (see Fig. 8 below). 
A  transmembrane segment from tissue factor was used to 
isolate the protein from intracellular events. The resulting 
stable transfectants were recognized specifically by multi- 
ple antibodies to CD44 as well as by the HPC4 antibody. 
While  the  transfected  cells  did  not  constitutively bind 
hyaluronan, recognition of as little as 1 ng/ml of FL-HA 
was  detectable  when  the  cells were pretreated  with  the 
IRAWB14  antibody  (Fig.  5).  Simple  exposure  to  the 
HPC4 antibody never increased ligand binding more than 
threefold over background (data not shown). CD44 which 
had been extensively cross-linked via the HPC4 epitope, 
followed by exposure to sheep anti-mouse IgG, could rec- 
ognize  above background  amounts  of this  ligand.  How- 
ever, binding leveled off at a low level and contrasted to 
the extraordinary recognition ability of cells treated with 
just the IRAWB14 antibody alone. These results suggest 
7O 
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50  U. 
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--  i  i  i  i 
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Figure 5.  Cross-linkage  of CD44 via an epitope tag slightly in- 
creases ligand-binding ability. Stable transfectants were prepared 
with AKR1 lymphoma cells and eDNA, which encodes the trans- 
membrane domain of tissue factor, the HPC4 epitope (see Fig. 8 
for placement), and the extracellular  portion of the hemopoietic 
form of CD44. Flow cytometry was first done to establish that the 
transfected CD44  was recognized  both by antibodies  to CD44 
and the HPC4 epitope tag (not shown). The cells were then ex- 
posed to FL-HA after pretreatment with the IRAWB14 or HPC4 
antibodies  alone, or HPC4 followed by a second antibody as de- 
scribed  in Materials  and Methods.  The results  are shown with 
background  fluorescence  obtained  with  untreated  cells  sub- 
tracted. 
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that while simple oligomerization of CD44 improves its re- 
ceptor function, the IRAWB14 antibody induces changes 
which have far greater consequences. 
Competition between the Hyaluronan Ligand and a 
Blocking Antibody for CD44 
A  single amino acid (histidine-83) determines the epitope 
recognized by the hyaluronan blocking KMll4 antibody; 
we  performed  simple  competition  experiments  between 
this  antibody  and  HA.  CD44  positive  AKR1.CD44WT 
lymphoma ceils were placed in graded concentrations of un- 
labeled hyaluronan before addition of fluorescein-labeled 
KMll4. The free ligand had no effect on antibody staining 
(Fig. 6, left panel). A reciprocal experiment was performed 
where  the  cells  were  first  exposed  to  fluorescent  hyal- 
uronan,  followed by unlabeled  KMll4  antibody (Fig.  6, 
right panel).  In this  situation,  as little  1  Ixg of antibody 
completely reversed  hyaluronan  binding.  The  IM7  anti- 
body, which fails to block ligand binding to these cells, also 
did not elute HA once it had attached. These experiments 
indicate that the ligand has a lower avidity and/or higher 
dissociation rate from CD44  than does the  KMll4  anti- 
body. KMll4 must either alter CD44 conformation so as 
to make hyaluronan recognition impossible or block the 
binding site. 
The Ability of CD44 Antibodies to Block Ligand 
Binding Depends on Cell Type as well as Specificity 
Previous studies revealed that although  CD44 is broadly 
aM2  WB 
J~  KMl14  KMl14 
Relative Fluorescence Intensity 
Figure 7.  Some antibodies  block HA recognition,  but only on 
particular cell lines. Flow cytometry results  are shown with a B 
cell hybridoma (BM2) and a T lymphoma (WB) which were ex- 
posed  to  unlabeled  CD44  antibodies  before FL-labeled  HA. 
Binding of HA via CD44 was completely blocked by the KM114 
antibody.  However, pretreatment with  the  IM7 antibody only 
prevented ligand recognition  by the WB lymphoma. 
Figure 6.  Competition between HA and anti- 
body for CD44  binding,  The left panel shows 
that even very high concentrations  of unlabeled 
HA  did  not  prevent  staining  of  AKR1.CD- 
44WT transfectants  with FITC labeled KMll4 
antibody. The right panel illustrates that labeled 
HA was eluted from prestained cells with the 
same antibody,  but not with IM7. The amount 
of label on cells was determined by flow cytom- 
etry and expressed as MFI. 
expressed on lymphocyte populations, only some cells are 
responsive to the enhancing IRAWB14 antibody (20, 24- 
27).  We  now  show  that  the  type  of  cell  can  influence 
whether certain antibodies interfere with hyaluronan rec- 
ognition by cells that do so constitutively. 9 of the 10 anti- 
bodies in the h  group efficiently blocked ligand binding, 
but only when examined with the WB lymphoma (Fig. 7 
and Table IV). As noted above, all antibodies whose spec- 
ificity was influenced  by histidine-83  or valine-90/threo- 
nine-91  were  uniform  blockers,  regardless  of cell  type. 
There was no correlation between the isotypes of the anti- 
bodies and their influence on CD44 function. 
Discussion 
While  considerable information suggests that  CD44 par- 
ticipates in tumor metastasis and other processes, its mo- 
lecular structure has not been solved and little is known 
about its ligand-binding site(s). We performed a  detailed 
analysis of a large panel of CD44 antibodies. This informa- 
tion can now be used to consider how the speciflcities of 
antibodies correspond to their abilities to influence ligand 
recognition functions. It also provides some basis for spec- 
ulation  about regions  of the molecule that contribute  to 
adhesive functions. 
Species Polymorphisms in CD44 that Are Immunogenic 
We  selected  the  interspecies  chimera  approach  because 
Table IV. Some CD44  Antibodies Only Block Ligand Binding 
by Particular Cells 
Cell lines 




KM114 (IgG1)  ,[,~,  ,[,~,  ~,$  ~,~. 
KM201 (IgGl)  $~  ~,~,  ~,,l,  ~,~, 
SK159 (IgG2a)  '["  ~"["  $  -~ 
IM7 (IgG~)  ,-~  ~  ,-~  ,1,~, 
SK47 (IgG2a)  ~  ~  ~  ~- 
IRAWB27.3 (IgGl)  ,-o  ,-o  ~  $ 
KM703 (IgG2~)  ~  ~  ,-o  ,~ 
Cells were incubated on ice with FITC-HA in the presence of the indicated CD44 an- 
tibodies for 15 rain. Binding was then assessed by flow cytometry. MFI of staining in 
the presence of each antibody was normalized to the MFI of FITC-HA alone of each 
cell line. 
Changes are indicated as: ,--~, 0-50%; $, 50-90%;  ,1,$, >90% decreases in FITC-HA 
binding. 
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ing, and many of the antibodies even failed to recognize 
reduced  protein.  All  of  the  chimeric  proteins  retained 
ligand-binding  ability and  thus reflected species  specific 
polymorphisms rather than mutations. Structural integrity 
of these molecules was  also suggested by the reciprocal 
loss of mouse-specific epitopes and gain of reactivity by 
antibodies to rat CD44. Furthermore, some rat antibodies 
to murine CD44 recognized other species in a pattern that 
corresponds to shared amino acids. For example, the IM7 
group of antibodies (epitope h) presumably recognize hu- 
man CD44 because it shares a proline at position 108 with 
mouse. Similarly, the KMll4 antibody recognizes hamster 
(shared histidine-83), but not human  CD44  (different at 
this position). A number of our antibodies recognize single 
residue differences between species, which in one case oc- 
curs at the amino terminus of the protein. While this type 
of analysis  does not precisely reveal epitopes  on  CD44 
which the antibodies recognize, it allows grouping of anti- 
bodies  according to  similar  specificity. We  also  assume 
that substitution of an amino acid subtly influences protein 
conformation within a limited area because rat and mouse 
CD44 are both functional receptors for HA. 
Some antibodies determined to have different specifici- 
ties by chimera  analysis  (groups d  and f)  were  able  to 
cross-block each other. This might advise caution in use of 
the term epitope mapping to describe results from simple 
antibody cross-blocking studies, because it implies that the 
precise locations of antibody binding sites are known. A1- 
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Figure 8.  The secondary  structure of CD44 has been extrapo- 
lated from that of the related cartilage link protein (11, 33). Posi- 
tions of residues determining some of the murine and rat CD44 
epitopes  are  indicated,  along  with  the position  of the HPC4 
epitope tag used for one construct.  Two shaded  areas  contain 
B(X7)B motifs which other studies indicate may be important for 
HA recognition (38, 56). 
though the h epitope is determined by a polymorphism at 
position 108 (proline), a fusion protein which stopped at 
threonine-113 was  not recognized by IM7.8.1  (40). This 
stretch of six residues is interrupted by a postulated disul- 
fide bond  (Fig.  8).  Structural integrity of the  h  epitope 
must therefore depend on residues in two neighboring re- 
gions of the molecule. 
The KM201  antibody is partially related to KM114 in 
that  its  recognition was  reduced, but not  eliminated by 
substitution of histidine-83 and it did not give significant 
staining with human lymphocytes in our hands. However, 
the same reagent has been found to interfere with func- 
tions  mediated  by  human  CD44  (19,  53).  This  species 
cross-reactivity might not be due to peptide sequence be- 
cause we recently found that tunicamycin-treated hamster, 
but not mouse, cells lose the KM201 epitope (18). 
Relationships  between Immunogenic Regions and 
Functional Domains 
Large numbers of mAbs have been prepared to distinct 
human CD44 epitopes, and at least some of them inhibit 
hyaluronan recognition (29, 30, 34, 42). The epitopes for 
most of these have not been characterized. An exception is 
the HERMES 3 antibody, which does not interfere with 
HA recognition, but does block human lymphocyte adhe- 
sion to high endothelial venules in mucosal tissues (7). The 
HERMES  3  epitope  is  encoded by amino  acids  in  the 
membrane  proximal  region  (11),  an  area  with  discrete 
functions not necessarily related to hyaluronan. This do- 
main is subject to great molecular diversity arising from 
alternative  mRNA  splicing  and  has  attracted  interest 
because of its possible function in cell migration and me- 
tastasis (12, 13, 45). Variation in this part of human CD44 
can also influence HA recognition in certain cell types (8, 
13, 49). This interesting region of the molecule was not de- 
tected by any of the anti-mouse CD44 antibodies used in 
our  study.  In  fact,  all  of these  reagents  recognized the 
truncated CD44ANC protein, which contains only the first 
163 residues (13). 
Solution of the structure of CD44 will likely reveal close 
physical  proximity between  different  loops.  Antibodies 
have been prepared that recognize combinatorial epitopes 
involving separate integrin chains (3, 5). We now describe 
an  antibody  (SK159)  whose  epitope  depends  on  three 
widely separated residues in the same protein. Available 
information indicates that multiple  CD44  domains must 
function in  concert for effective hyaluronan recognition 
and these antibodies may be helpful in understanding their 
spatial orientation. 
CD44 can mediate recognition of ligands other than hy- 
aluronan  and  some  of these  functions  may involve the 
amino  terminal  domains.  For  example,  it  has  been  re- 
ported that hyaluronan and a proteoglycan might compete 
for the same site on CD44, in a manner inhibitable by the 
KM201  antibody (54). Also, the interaction between an 
erythroleukemia line and stromal cells seemed not to be 
hyaluronan dependent, but was partially blocked by our 
KM81  antibody (51).  Precursors of thymocytes have no 
apparent affinity for hyaluronan, but their migration to the 
thymus is blocked by pretreatment with either the IM7 or 
KM201 antibodies (22, 57). 
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are required for efficient CD44-hyaluronate interactions 
(13, 40). Furthermore, ligand-binding ability is  probably 
dependent in part on critically spaced disulfide bonds (35). 
For these reasons, information is very limited on residues 
that might contribute to the actual binding site. One study 
concluded that two short stretches of amino acids corre- 
sponding to a B(X7)B motif (see Fig. 8) had affinity for 
HA when expressed as peptide-bacterial fusion proteins 
(58). In another study, mutation of a single arginine in one 
of these motifs completely abolished HA recognition and 
function was greatly reduced following alterations or trun- 
cations of the other motif (40). These motifs and the se- 
quences which surround them  are identical in mice and 
rats.  Immunogenic residues  corresponding to  antibodies 
that influence ligand binding were not obviously localized 
to these portions of murine  CD44  (Fig.  8).  Rather,  our 
findings indicate that some features of the molecule dic- 
tated by lysine 49 (group d, some enhancing antibodies) 
and the histidine 83 to valine 90 region (group f, blocking 
antibodies) could be important in regulating its adhesive 
function. 
Antibodies that Block Ligand Recognition 
High concentrations of unlabeled HA had no effect on at- 
tachment  of the  KMl14  antibody to  CD44  and  KMl14 
eluted previously bound ligand from cells. This universal 
blocking antibody may have higher affinity for CD44 than 
does  the  ligand,  and  it  either  causes  a  conformational 
change or physically obstructs the binding site. Antibodies 
with indistinguishable, or partially related specificities (KM81 
and KM201, RAMBM55.5, and D12), also blocked hyalu- 
ronan binding in every situation. SK159 was another con- 
sistent blocking antibody and one of the three residues on 
which its epitope depends is in the same loop of the mole- 
cule. While it is premature to speculate on the actual bind- 
ing site for HA, this portion of CD44 may well contribute 
to it. 
All  but  one  of the  antibodies  in  another  group  (h), 
blocked hyaluronan recognition by some cells, but not by 
others (Table IV). The basis for these cell-specific effects 
are not known. It might be speculated that WB cells recog- 
nize HA with relatively low affinity, allowing the binding 
to be inhibited by a broader spectrum of antibodies. Alter- 
natively, it is possible that different ceils use different por- 
tions of CD44 to achieve the same function. We show else- 
where that  the  ability of some cells to bind HA can be 
largely  explained  by  differential  glycosylation of CD44 
(18, 28).  Treatment with tunicamycin or deglycosylating 
enzymes  converts  nonbinding  cells  to  HA-recognizing 
cells. It will be interesting to learn if there are similarities 
in how  antibodies  and naturally occurring carbohydrate 
make the CD44 binding site inaccessible for ligand. 
Antibodies that Enhance Ligarut Binding 
It remains unclear why the IRAWB14 antibody increases 
hyaluronan recognition by some lymphocytes, but it could 
mimic some naturally occurring structure on the same or 
apposing  cells.  Antibodies  to  several  integrins  are  also 
known to activate receptors for ligand recognition, and it 
has been speculated the antibodies cause and/or maintain 
a favorable conformational state in the receptors (2, 9, 38, 
48). We anticipated that antibodies with related specificity 
would similarly increase hyaluronan recognition, but this 
was not the case and there was also no correlation with Ig 
isotype.  A  previous  study  localized  residues  encoding 
epitopes for both activating and inhibiting antibodies to a 
short segment of the [~1 integrin chain (52). This region in- 
cluded four amino acids that differed between species. We 
found that antibodies with indistinguishable specificity for 
polymorphism of a single residue had opposite influence 
on hyaluronan binding.  Furthermore, only 1  out  of an- 
other group of 10 antibodies (R7166.7, group h) had en- 
hancing activity. One residue difference between mice and 
rats could result in more than one epitope and the block- 
ing and enhancing antibodies within one group could dif- 
fer with respect to fine specificity. Other properties of an- 
tibodies, such as affinity or isoelectric point, might also be 
important for determining how they influence cell adhe- 
sion molecules. 
All of the antibodies in our panel recognize the portions 
of CD44 that are conserved among HA-recognizing pro- 
teins. We wondered if antibodies directed to a completely 
different part of the molecule could influence HA recogni- 
tion and designed constructs with the HPC4 epitope tag 
near the cell membrane  (Fig. 8).  A  transmembrane  do- 
main from tissue factor was used, as it is known to be com- 
patible with dimerization (44). A small but measurable in- 
crease was seen when the receptor was extensively clustered 
via the epitope tag and a second antibody (Fig. 5). A poly- 
clonal antibody prepared to a membrane proximal peptide 
of human CD44 also had a slight positive influence on hy- 
aluronan binding (30). These findings are compatible with 
previous studies  which  demonstrated  a  requirement for 
multivalent binding of enhancing CD44  antibodies  (26). 
Artificial dimers of CD44 have been shown to have im- 
proved ligand recognition (41). Local densities of integrins 
and their ligands have also been thought to be important 
for cell adhesion (14). However, the degree of ligand bind- 
ing we achieved by receptor cross-linkage plateaued at a 
much lower level than that caused by IRAWB14. We show 
elsewhere  that  IRAWB14  substantially  increased  the 
ligand binding ability of a purified CD44-Ig fusion protein, 
even after it was immobilized to beads (18). Thus, while 
clustering of CD44 molecules on cell membranes can in- 
fluence the  amount  of l!gand bound,  interaction with  a 
special type of antibody (or ligands it might mimic) can 
have a much greater effect. 
These observations add to previous studies by helping to 
ascribe  functions  to  particular  CD44  domains.  There 
might  be  naturally  occurring  substances  that  modulate 
ligand recognition by this cell adhesion molecule. Our ob- 
servations with enhancing and inhibiting antibodies indi- 
cate that such regulatory molecules could function through 
multiple sites and mechanisms. An understanding of these 
phenomena might suggest means to influence CD44 medi- 
ated tumor metastasis. Also, experience obtained with this 
group of reagents may influence the design and interpreta- 
tion of many other studies in which antibodies are used to 
probe  and  manipulate  functions  of cell  adhesion  mole- 
cules. 
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